New Study Presented: Lactobacillus reuteri Protectis Reduced Crying Time in Infants With Colic

STOCKHOLM, June 15, 2010 - After only one week of supplementation the reduction in daily crying time
was 74 % among the infants supplemented by L. reuteri Protectis compared to
38 % in the placebo group. At the end of the study there was a significant
difference between the two groups.

(Logo:
www.newscom.com/cgi-bin/prnh/20100615/394961 )

- These results are in line with previous studies on colics and confirm
the benefit of L. reuteri in colicky infants, says Doctor Francesco Savino,
Department of Paediatrics, Regina Margherita Children's Hospital, University
of Turin, Italy.

To view the Multimedia News Release, please click:

multivu.prnewswire.com/mnr/prne/biogaia/42443/

In this double blind, placebo controlled study 50 infants with confirmed
infantile colic were randomly assigned to two treatments: L. reuteri
Protectis drops 108 CFU per day or placebo for 21 consecutive days.

The primary outcome was a reduction in average crying time to less than
three hours per day, which is the limit of colic, by day 21. On day 21, 84 %
of the L. reuteri Protectis supplemented infants had resolved their colic
(dropped to less than three hours of crying), a significantly higher number
compared to 43% in the placebo group (p<0.05).

At the time of inclusion the median crying time per day was 370 minutes
in the probiotic group and 300 minutes in the placebo group. On day seven the
crying time had been reduced by 74 %, to 95 minutes, in the L. reuteri
Protectis group and to 185 minutes in the placebo group (p=0.082). At the end
of the study there was a significant difference in median daily crying time
between the groups, 35 minutes in the L. reuteri Protectis group versus 90
minutes in the placebo group (p<0.05).

The proportion of infants responding to the supplementation, defined as a
50 % or greater reduction in median crying time, was significantly greater in
the L. reuteri Protectis group compared to the placebo group at day 7, 14 and
21 of the study.

    - The data with L. reuteri are convincing and confirm, in a
      placebo-controlled study, our earlier data with this probiotic. We
      believe these results will have an impact on the treatment of infants
      with colic, says Doctor Savino.

The study was presented on the Annual Meeting of ESPGHAN in Istanbul on
the 10th of June 2010.

BioGaia is a biotechnology company that develops, markets and
sells probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri),
which has probiotic, health-enhancing effects. The class B share of the
Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX
Nordic Exchange Stockholm.

www.biogaia.com

Photo:
www.newscom.com/cgi-bin/prnh/20100615/394961

Video:
multivu.prnewswire.com/mnr/prne/biogaia/42443/

For additional information contact: Francesco Savino, MD, PhD, Dept Paediatrics, Regina Margherita Children's Hospital, Turin: +39-335-801-8901 (mobile) or francesco.savino at unito.it; Eamonn Connolly, Senior Vice President Research, BioGaia AB: +46-8-555-293-00 or ec at biogaia.se; Peter Rothschild, President, BioGaia AB: +46-8-555-293-00 or
pr at biogaia.se